摘要
小细胞肺癌的药物治疗仍面临很大的挑战。局限期小细胞肺癌的标准治疗方案为基于铂类药物的化疗方案联合胸部放疗和预防性全脑放疗。对广泛期小细胞肺癌,化疗仍然是主要的治疗方法,必要时还可进行局部放疗。随着新型化疗药物、分子靶向药物和免疫调节剂的不断涌现,小细胞肺癌药物治疗有了更多的实际选择,但治疗结果迄今并未获得实质性的进步,有待今后进一步的深入研究。
Treatment of small cell lung cancer （SCLC） remains a great challenge for oncologists. Generally, limited-stage SCLC can be treated with platinum-based chemotherapy plus concurrent chest radiotherapy and prophylactic cranial irradiation while extensive-stage SCLC can be considered for a platinum-based chemotherapy, and palliative irradiation if needed. Newer chemotherapy agents, molecular-targeted drugs, as well as immunomodulators have provided more choices for SCLC treatment, but no real progress has been made so far, emphasizing the need for a better understanding of the molecular mechanisms and therapeutic targets.
出处
《上海医药》
CAS
2015年第15期3-8,13,共7页
Shanghai Medical & Pharmaceutical Journal
基金
上海市科学技术委员会基金资助项目(编号:124119a6200)
关键词
小细胞肺癌
化疗药物
分子靶向药物
免疫调节剂
small cell lung cancer
chemotherapy agents
molecular-targeted drugs
immunomodulators
